Dupilumab was first approved for the treatment of atopic dermatitis (AD) and blocks the
signaling of interleukin (IL)-4 and-13. Several other chronic skin conditions share …

In recent years, studies have associated dupilumab with unmasking or progression of
cutaneous T‐cell lymphoma (CTCL). The objective of this study was to synthesize reported …

Among the new biological therapies for atopic diseases, dupilumab is a fully human
monoclonal antibody directed against IL-4Rα, the common chain of interleukin-4 and …

Dupilumab, a monoclonal antibody inhibiting interleukin (IL) 4 and IL‐13, is approved for the
treatment of moderate to severe atopic dermatitis (AD) in children aged≥ 6 years …

Type 2 immunity, illustrated by T helper 2 lymphocytes (Th2) and downstream cytokines (IL-
4, IL-13, IL-31) as well as group 2 innate lymphoid cells (ILC2), is important in host defense …

Cutaneous T-cell lymphoma (CTCL) comprises a group of lymphoproliferative diseases
characterized by the accumulation of malignant T cells in chronically inflamed skin lesions …

Primary cutaneous T-cell lymphomas (CTCL), which include mycosis fungoides (MF) and
Sézary syndrome (SS), are a group of lymphoproliferative disorders characterized by clonal …

Background: Mycosis fungoides (MF) and Sezary Syndrome (SS) are the most common
cutaneous T-cell lymphomas. It has been hypothesized that the interaction between the …

Introduction: Dupilumab, the first biologic drug to be approved for the treatment of moderate
to severe atopic dermatitis in adolescents and adults, has shown efficacy and safety in …

Background Cutaneous T-cell lymphoma following biologic therapy is extremely rare.
Objective The aim of this systematic review was to investigate the development of cutaneous …